Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

ISJ Merkies; IN van Schaik; JM Léger; V Bril; N van Geloven; HP Hartung; RA Lewis; G Sobue; JP Lawo; BL Durn; DR Cornblath; JL De Bleecker; C Sommer; W Robberecht; M Saarela; J Kamienowski; Z Stelmasiak; B Tackenberg; O Mielke; A Sabet; K George; L Roberts; R Carne; S Blum; R Henderson; P Van Damme; J Demeestere; S Larue; C D'Amour; P Kunc; M Valis; J Sussova; T Kalous; R Talab; M Bednar; T Toomsoo; I Rubanovits; K Gross-Paju; U Sorro; M Auranen; J Pouget; S Attarian; GL Masson; A Wielanek-Bachelet; C Desnuelle; E Delmont; P Clavelou; D Aufauvre; J Schmidt; J Zschuentzsch; C Sommer; D Kramer; O Hoffmann; C Goerlitz; J Haas; M Chatzopoulos; R Yoon; R Gold; P Berlit; A Jaspert-Grehl; D Liebetanz; A Kutschenko; M Stangel; C Trebst; P Baum; F Bergh; J Klehmet; A Meisel; F Klostermann; J Oechtering; H Lehmann; M Schroeter; T Hagenacker; D Mueller; A Sperfeld; F Bethke; V Drory; A Algom; D Yarnitsky; B Murinson; A Di Muzio; F Ciccocioppo; S Sorbi; S Mata; A Schenone; M Grandis; G Lauria; D Cazzato; G Antonini; S Morino; D Cocito; M Zibetti; T Yokota; T Ohkubo; T Kanda; M Kawai; K Kaida; H Onoue; S Kuwabara

Journal article

Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies

ISJ Merkies, IN van Schaik, JM Léger, V Bril, N van Geloven, HP Hartung, RA Lewis, G Sobue, JP Lawo, BL Durn, DR Cornblath, JL De Bleecker, C Sommer, W Robberecht, M Saarela, J Kamienowski, Z Stelmasiak, B Tackenberg, O Mielke, A Sabet Show all

Journal of the Peripheral Nervous System | WILEY | Published : 2019

DOI: 10.1111/jns.12302

Download PDF

Abstract

Intravenous immunoglobulin (IVIG) is a potential therapy for chronic inflammatory demyelinating polyneuropathy (CIDP). To investigate the efficacy and safety of the IVIG IgPro10 (Privigen) for treatment of CIDP, results from Privigen Impact on Mobility and Autonomy (PRIMA), a prospective, open-label, single-arm study of IVIG in immunoglobulin (Ig)-naïve or IVIG pre-treated subjects (NCT01184846, n = 28) and Polyneuropathy And Treatment with Hizentra (PATH), a double-blind, randomized study including an open-label, single-arm IVIG phase in IVIG pre-treated subjects (NCT01545076, IVIG restabilization phase n = 207) were analyzed separately and together (n = 235). Efficacy assessments included ..

View full abstract